Prosthesis (i.e. – artificial body members) – parts thereof – or ai – Arterial prosthesis – Drug delivery
Reexamination Certificate
2008-04-29
2010-02-16
Sweet, Thomas J (Department: 3774)
Prosthesis (i.e., artificial body members), parts thereof, or ai
Arterial prosthesis
Drug delivery
C623S001430
Reexamination Certificate
active
07662178
ABSTRACT:
This invention provides a stent for implantation in a blood vessel or other tissue, wherein the stent is coated with or contains C3 exoenzyme, a chimeric version thereof or an inhibitor of RhoA. This invention also provides a method for treating or inhibiting the onset of restenosis in a subject which comprises implanting one of the instant stents in the subject's blood vessel.
REFERENCES:
patent: 5163952 (1992-11-01), Froix
patent: 5304121 (1994-04-01), Sahatjian
patent: 5804604 (1998-09-01), Frankel
patent: 5851786 (1998-12-01), Johnson
patent: 6153252 (2000-11-01), Hossainy et al.
patent: 6179817 (2001-01-01), Zhong et al.
patent: 6306166 (2001-10-01), Barry et al.
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6306993 (2001-10-01), Rothbard et al.
patent: 6316003 (2001-11-01), Frankel
patent: 6344035 (2002-02-01), Chudzik et al.
patent: 6358556 (2002-03-01), Ding et al.
patent: 6379382 (2002-04-01), Yang
patent: 6387124 (2002-05-01), Buscemi et al.
patent: 6391052 (2002-05-01), Buirge et al.
patent: 6495663 (2002-12-01), Rothbard et al.
patent: 6558733 (2003-05-01), Hossainy et al.
patent: 6579847 (2003-06-01), Unger
patent: 6767544 (2004-07-01), Brooks et al.
patent: 6776991 (2004-08-01), Naumann
patent: 6958147 (2005-10-01), Alitalo et al.
patent: 2002/0041898 (2002-04-01), Unger et al.
patent: 2003/0077310 (2003-04-01), Pathak et al.
patent: 2003/0130722 (2003-07-01), Marx et al.
patent: 2002-193838 (2002-07-01), None
patent: WO 03/059192 (2003-07-01), None
Barth, H., Hofmann, F., Olenik, C., Just, I. and Aktories, K. (1998) The N-terminal part of the enzyme component (C2I) of the binaryClostridium botulinumC2 toxin interacts with the binding component C2II and functions as a carrier system for a Rho ADP-ribosylating C3-like fusion toxin. Infect. Immun. 66: 1364-1369.
Boquet, P., Popoff, M.R., Giry, M., Lemichez, E. and Bergez-Aullo, P. (1995) Inhibition of p21 Rho in intact cells by C3 diptheria toxin chimera proteins. Methods Enzymol. 256: 297-306.
Brugidou, J., Legrand, C., Mery, J. and Rabie, A. (1995) The retro-inverso form of a homeobox-derived short peptide is rapidly internalised by cultured neurones: a new basis for an efficient intracellular delivery system. Biochem. Biophys. Res. Comm. 214(2): 685-693.
Cao, W., Mohacsi, P., Shorthouse, R., Pratt, R., and Morris, R. (1995) Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis:inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 59: 390-395.
Dillon, S.T., and Feig, L.A. (1995) Purification and assay of recombinant C3 transferase. Methods in Enzymology 256: 174-184.
Gallo, R., Padurean, A., Jayaraman, T., Marx, S.O., Roque, M., Adelman, S., Chesebro, J., Fallon, J., Fuster, V., Marks, A.R., and Badimon, J.J. (1999) Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 99: 2164-2170.
Gregory, C., Huie, P., Billingham, M., and Morris, R. (1993) Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Transplantation 55: 1409-1418.
Kato, J.M., Matsuoka, M., Polyak, K., Massaque, J., and Sherr, C.J. (1994) Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27kipl) of cyclin-dependent kinase-4 activation. Cell 79: 487-496.
Kishi, H., Bao, J., Kohama, K. (2000) Inhibitory effects of ML-9, wortmannin, and Y-27632 on the chemotaxis of vascular smooth muscle cells in response to platelet-derived growth factor-BB. J. Biochem. (Tokyo) 128(5): 719-22.
Lerner, E.C., Qian, Y., Hamilton, A.D. and Sebti, S.M. (1995) Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J. Biol. Chem. 270: 26770-26773.
Luo, Y., Marx, S.O., Kiyokawa, H., Koff, A., Massague, J., and Marks, A.R. (1996) Rapamycin resistance tied to defective regulation of p27kipl. Mol. Cell. Biol. 16: 6744-6751.
Marx, S.O., Jayaraman, T., Go, L.O. and Marks, A.R. (1995) Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 76: 412-417.
Marx, S.O. and Marks, A.R. (2001) Bench to bedside: The development of rapamycin and its application to stent restenosis. Circulation 104: 852-855.
Ménétrey, J., Flatau, G., Stura, E.A., Charbonnier, J.B., Gas, F., Teulon, J.M., Le Du, M.H., Boquet, P. and Menez, A. (2002) NAD binding induces conformational changes in Rho ADP-ribosylatingClostridium botulinumC3 exoenzyme. J. Biol. Chem. 277: 30950-30957.
Negoro, N., Hoshiga, M., Seto, M., Kohbayashi, E., Ii, M., Fukui, R., Shibata, N., Nakakoji, T., Nishiguchi, F., Sasaki, Y., Ishihara, T. and Ohsawa, N. (1999) The kinase inhibitor fasudil (HA-1077) reduces intimal hyperplasia through inhibiting migration and enhancing cell loss of vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 262: 211-215.
Nemoto, Y., Namba, T., Kozaki, S. and Narymiya, S. (1991) Clostridium botulinum C3 ADP-ribosyltransferase gene. Cloning, sequencing, and expression of a functional protein inEscherichia coli. J. Biol. Chem. 266: 19312-19319.
Nourse, J., Firpo, E., Flanagan, W.M., Coats, S., Polyak, K., Lee, M., Massague, J., Crabtree G., and Roberts, J.M. (1994) Interleukin-2-mediated elimination of the p27kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature (London) 372: 570-573.
Park, J., Ryu, J., Kim, K.-A., Lee, H.J., Bahn, J.H., Han, K., Choi, E.Y., Lee, K.S., Kwon, H.Y. and Choi, S.Y. (2002) Mutational analysis of a human immunodeficiency virus type 1 Tat protein transduction domain which is required for delivery of an exogenous protein into mammalian cells. J. of General Virology 83: 1173-1181.
Poon, M., Marx, S.O., Gallo, R., Badimon, J.J., Taubman, M.B. and Marks, A.R. (1996) Rapamycin inhibits vascular smooth muscle cell migration. J. Clin. Invest. 98: 2277-2283.
Popoff, M.R., Boquet, P., Gill, D.M. and Eklund, M.W. (1990) DNA sequence of exoenzyme C3, an ADP-ribosyltransferase encoded byClostridium botulinumC and D phages. Nucl. Acids Res. 18: 1292.
Popoff, M.R., Hauser, D., Boquet, P., Eklund, M.W. and Gill, D.M. (1991) Characterization of the C3 gene ofClostridium botulinumtypes C and D and its expression inEscherichia coli. Infect. Immun. 59: 3673-3679.
Rensing, B.J., Vos, J., Smits, P.C., Foley, D.P., van den Brand, M.J.B.M., van der Giessen, W.J., de Feijter, P.J. and Serruys, P.W. (2001) Coronary restenosis elimination with a sirolimus eluting stent; first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. European Heart Journal 22: 2125-2130.
Schwartz, R.S., Edelman, E.R., Carter, A., Chronos, N., Rogers, C., Robinson, K.A., Waksman, R., Weinberger, J., Wilensky, R.L., Jensen, D.N., Zuckerman, B.D. and Virmani, R. (2002) Drug-eluting stents in preclinical studies: recommended evaluation from a concensus group. Circulation 106: 1867-1873.
Schwartz, S.M. (1997) Smooth muscle migration in atherosclerosis and restenosis. J. Clin. Invest. 100: S87-89.
Seasholtz, T.M., Majumdar, M., Kaplan, D.D. and Brown, J.H. (1999) Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ. Res. 84: 1186-1193.
Sousa, J.E., Costa, M.A., Abizaid, A., Abizaid, A.S., Feres, F., Pinto, I.M.F. et al. (2000) Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries. A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 102: r54-r57.
Sousa, J.E, Costa, M.A., Abizaid, A.C. Rensing, B.J., Abizaid, A.S. et al. (2001) Sustained supression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular untrasound follow-up. Circulation 104: 2007-2011.
Sun, J., Marx, S.O., Chen, H-J., Poon, M., Marks, A.R. and Rabbani, L.E. (2001) Role for p27 (Kip1) in vascular smooth muscle cell migration. Circulation 103: 2967-2972.
Wender, P.A., Mitchell, D.J., Pattabiraman, K., Pelkey, E.T., Steinman, L. and Rothbard
Marks Andrew R.
Marx Steven O.
Cooper & Dunham LLP
Sweet Thomas J
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
C3 exoenzyme-coated stents and uses thereof for treating and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with C3 exoenzyme-coated stents and uses thereof for treating and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C3 exoenzyme-coated stents and uses thereof for treating and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4208205